With the method of managing the clinical supply chain in clinical trials firmly established through a period of trial and error along with continual adjustment over decades, it is time to take another look at the current paradigm with the new technologies and processes available. Specifically, we will view the growth in understanding for how data integration can bring huge improvements in operational efficiency and lower clinical material waste levels.
What is the current state?
Genuine innovation well beyond current capabilities, i.e., a revolution is required to bring about the capabilities that the industry is crying out for.
Where are the restrictions? Every organisation has any number of clinical trial solutions which are often old, inflexible, and usually difficult to use, let alone extract meaningful data from. But nonetheless, these solutions and processes manage to survive and become established.
How do we use IRT today?
There are many IRT providers available, most of which offer study IRT build flexibility according to individual study designs and differing supply models. Pharma sponsors tend to align themselves with one or two primary IRT providers, ideally with standards in place to reduce cost and improve repeatability and familiarity.
- Lorem ipsum mi tincidunt mauris
Remember, not all innovation is equal. And not all of it is relevant. With a constant flood of new technologies and ideas, it’s easy to lose focus or invest in initiatives that don’t work.
- Lorem ipsum mi tincidunt mauris
Remember, not all innovation is equal. And not all of it is relevant. With a constant flood of new technologies and ideas, it’s easy to lose focus or invest in initiatives that don’t work.
- Lorem ipsum mi tincidunt mauris
Remember, not all innovation is equal. And not all of it is relevant. With a constant flood of new technologies and ideas, it’s easy to lose focus or invest in initiatives that don’t work.
- Lorem ipsum mi tincidunt mauris
Remember, not all innovation is equal. And not all of it is relevant. With a constant flood of new technologies and ideas, it’s easy to lose focus or invest in initiatives that don’t work.
How do we use IRT today?
There are many IRT providers available, most of which offer study IRT build flexibility according to individual study designs and differing supply models. Pharma sponsors tend to align themselves with one or two primary IRT providers, ideally with standards in place to reduce cost and improve repeatability and familiarity.
- Lorem ipsum mi tincidunt mauris
Remember, not all innovation is equal. And not all of it is relevant. With a constant flood of new technologies and ideas, it’s easy to lose focus or invest in initiatives that don’t work.
- Lorem ipsum mi tincidunt mauris
Remember, not all innovation is equal. And not all of it is relevant. With a constant flood of new technologies and ideas, it’s easy to lose focus or invest in initiatives that don’t work.
- Lorem ipsum mi tincidunt mauris
Remember, not all innovation is equal. And not all of it is relevant. With a constant flood of new technologies and ideas, it’s easy to lose focus or invest in initiatives that don’t work.
- Lorem ipsum mi tincidunt mauris
Remember, not all innovation is equal. And not all of it is relevant. With a constant flood of new technologies and ideas, it’s easy to lose focus or invest in initiatives that don’t work.
How do we use IRT today?
There are many IRT providers available, most of which offer study IRT build flexibility according to individual study designs and differing supply models. Pharma sponsors tend to align themselves with one or two primary IRT providers, ideally with standards in place to reduce cost and improve repeatability and familiarity.
